Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC - Episode 5

Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition

December 14, 2023

Joshua K. Sabari, MD, Edward B. Garon, MD, MS

A comprehensive review of hepatotoxicity in ongoing studies evaluating KRAS inhibitors in the frontline setting, highlighting adagrasib and sotorasib in the KRYSTAL-7 and CodeBreaK 100 studies, respectively.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: The State of Targeted Therapies in NSCLC

EP. 2: Frontline Treatments for KRAS G12C-Mutation mNSCLC

EP. 3: Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations

EP. 4: The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC

Now Viewing

EP. 5: Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition

EP. 6: Disease Progression Beyond Frontline KRAS G12C Inhibitors

EP. 7: CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

EP. 8: KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

EP. 9: Practical Management of Hepatotoxicity in KRAS G12C Inhibitors

EP. 10: Future Perspectives in KRAS G12C-Mutated NSCLC